Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Benign Hematology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Benign Hematology

Expert Opinion / Commentary · November 19, 2018

2018 Top Stories in Benign Hematology: Severe Thalassemias

Written by
Michael H. Kroll MD

 

 Save  Recommend
 Share

Additional Info

  1. Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018;378(16):1479-1493.
  2. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
  3. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):417-496
  4. Paulson RF. Targeting a new regulator of erythropoiesis to alleviate anemia. Nat Med. 2014;20(4):334-335.
  5. Komrokji R, Garcia-Manero G, Ades L, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018;5(2):e63-e72.
  6. Cappellini MD, Porter J, Origa R, et al. Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase 2, open-label, dose-finding study. Haematologica. 2018 Oct 18. doi: 10.3324/haematol.2018.198887. [Epub ahead of print.]
  7. Taher AT, Cappellini MD. How I manage medical complications of β-thalassemia in adults. Blood. 2018;132(17):1781-1791.
  8. Casu C, Nemeth E, Rivella S. Hepcidin agonists as therapeutic tools. Blood. 2018;131(16):1790-1794.
  9. Machogu EM, Machado RF. How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders. Blood. 2018;132(17):1770-1780.
  10. Ballas SK, Zeidan AM, Duong VH, et al. The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: a systematic review. Am J Hematol. 2018;93(7):943-952.

Disclosure statements are available on the authors' profiles:

Michael Kroll MD

Further Reading

Recently Updated